How does Lipo C compare to other weight loss injections like liraglutide or phentermine? Lipo C works through hepatic lipid metabolism support rather than appetite suppression or thermogenesis, making it mechanistically distinct from GLP-1 agonists (liraglutide, semaglutide) and sympathomimetic stimulants (phentermine)
In this way, a significant amount of the active ingredient is used, and that guarantees the product's effectivity
Full text Fras JP, et al
Youre not alone, and youre not broken
McGarry S v., Cruickshank D, Iloba I, Jensen GS
What's New: July 2026 Update TRIUMPH-1 CONFIRMED (May 21, 2026): 28.3% average weight loss at 80 weeks in 2,339 patients Eli Lilly's pivotal Phase 3 obesity trial met all primary and key secondary endpoints 45.3% of patients on 12mg lost 30% of body weight surgical-level outcomes confirmed in the largest retatrutide trial to date 104-week extension: patients with BMI 35 reached up to 30.3% average weight loss weight loss did not plateau at 80 weeks TRANSCEND-T2D-1 CONFIRMED (topline March 2026, published June 2026): First completed Phase 3 trial in type 2 diabetes up to -2.0% HbA1c reduction and 16.8% weight loss in 537 patients, a separate program from TRIUMPH OSA data confirmed (ADA June 6, 2026): TRIUMPH-1's nested sleep apnea substudy showed 60.6% AHI reduction from a baseline of 58.6 events/hour NDA on track: Industry estimates continue to expect Q4 2026 filing following TRIUMPH-1 and TRIUMPH-4 data TRIUMPH-2 and TRIUMPH-3 results still expected later in 2026 this page updates monthly Current Status: Where Things Stand Retatrutide is an investigational medication developed by Eli Lilly
